carl icahn biogen
Anyway, Icahn concludes, “We believe ImClone and Biogen Idec situations analogous.” Among his several proposals is a request for the board to look at splitting BIIB into two units: one focused on cancer, the other on neurology.
At the time, Denner was senior managing director at Icahn Partners LP and was seated after two years of proxy battling by Carl Icahn, who wanted a Biogen split-up or sale.
BOSTON (MarketWatch) — Biogen Idec said Monday that it and activist investor Carl Icahn have agreed on two new appointments to the company’s board, thereby avoiding a repeat of …
New Purchase: Biogen Idec Inc. Carl Icahn initiated holdings in Biotechnology company Biogen Idec Inc.. His purchase prices were between $45.02 and $53.55, with an estimated average price of $48.8. The impact to his portfolio due to this purchase was 3.42%.
Board gives green light to evaluate suitors for the company. Biogen also has been approached by activist investor Carl Icahn, who recently purchased a small stake in the business. It said that it has received other “expressions of interest” as well, but would not elaborate.
BOSTON, April 8 (Reuters) – Billionaire investor Carl Icahn filed suit on Tuesday to force biotechnology company Biogen Idec Inc to hand over records related to the company’s recent failed attempt to …
Mar 23, 2010 · Fresh from winning a deal with Biogen Idec to add a director to the biotechnology company’s board, Carl C. Icahn has once again turned his attention to the notion of selling off the firm, Icahn to Push for Sale of Biogen, Report Says Search.
Carl Icahn is known for his activist investing and his investment performance has been good: since inception of 2004, his partnership Icahn Captial returned a total of 41.3%, beating S&P500’s 5.9%. In 2009, the partnership returned 31.9%, also beating S&P 500, as he disclosed in his 4Q09 letter to shareholders (see a copy at the end of this articles).
Carl Icahn. Carl Celian Icahn (born February 16, 1936) is an American businessman, investor, and philanthropist. He is the founder and controlling shareholder of Icahn Enterprises, a diversified conglomerate holding company based in New York City, formerly known …
Carl Icahn. As a leading shareholder activist, Carl Icahn’s efforts have unlocked billions of dollars of shareholder and bondholder value and have improved the competitiveness of American companies. He and his affiliated companies currently own businesses in a wide range of industries, including real estate, telecommunications, transportation,
Carl Icahn released his 13F for the quarter ended June, 30 2011. Notably, Icahn liquidated his stake in Biogen Idec, Inc. (NASDAQ: BIIB), Chesapeake Energy Corp. (NYSE: CHK) and lowered stakes in